Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.

Autor: Barsheshet Y; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Voloshin T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Brant B; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Cohen G; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Koren L; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Blatt R; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Cahal S; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Haj Khalil T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Zemer Tov E; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Paz R; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Klein-Goldberg A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Tempel-Brami C; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Jacobovitch S; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Volodin A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Kan T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Koltun B; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., David C; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Haber A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Giladi M; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Weinberg U; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Palti Y; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 15; Vol. 23 (22). Date of Electronic Publication: 2022 Nov 15.

In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso.

Autor: Blatt R; Novocure Ltd, Haifa, Israel., Davidi S; Novocure Ltd, Haifa, Israel., Munster M; Novocure Ltd, Haifa, Israel., Shteingauz A; Novocure Ltd, Haifa, Israel., Cahal S; Novocure Ltd, Haifa, Israel., Zeidan A; Novocure Ltd, Haifa, Israel., Marciano T; Novocure Ltd, Haifa, Israel., Bomzon Z; Novocure Ltd, Haifa, Israel., Haber A; Novocure Ltd, Haifa, Israel., Giladi M; Novocure Ltd, Haifa, Israel., Weinberg U; Novocure Ltd, Haifa, Israel., Kinzel A; Novocure GmbH, Munich, Germany., Palti Y; Novocure Ltd, Haifa, Israel.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Jun 24; Vol. 11, pp. 670809. Date of Electronic Publication: 2021 Jun 24 (Print Publication: 2021).

Immunogenic Cell Death Induced by Tumor Treating Fields (TTFields) Enhances Efficacy When Combined with Anti-PD-1 Therapy in Lung and Colon Cancer Animal Models

Autor: Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Schneiderman, R.S., Zeevi, E., Gotlib, K., Blatt, R., Cahal, S., Giladi, M., Kirson, E., Weinberg, U., Palti, Y.

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 September 2019 105(1) Supplement:E652-E652

Immunomodulatory Effect of Tumor Treating Fields (TTFields) Results in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy in Mouse Model of Lung Cancer

Autor: Voloshin, T. ¹, Davidi, S. ¹, Porat, Y. ¹, Shteingauz, A. ¹, Munster, M. ¹, Kaynan, N. ¹, Schneiderman, R.S. ¹, Brami, C. Tempel ¹, Zeevi, E. ¹, Gotlib, K. ¹, Cahal, S. ¹, Itzhaki, A. ¹, Giladi, M. ², Kirson, E. ², Weinberg, U. ¹, Kinzel, A. ³, Palti, Y. ¹

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 May 2019 104(1):237-237

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.

Autor: Voloshin T; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Kaynan N; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Davidi S; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Porat Y; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Shteingauz A; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Schneiderman RS; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Zeevi E; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Munster M; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Blat R; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Tempel Brami C; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Cahal S; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Itzhaki A; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Giladi M; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel. mosheg@novocure.com., Kirson ED; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Weinberg U; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel., Kinzel A; Novocure GmbH, Munich, Germany., Palti Y; Novocure Ltd., Topaz Building, MATAM Center, 31905, Haifa, Israel.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Jul; Vol. 69 (7), pp. 1191-1204. Date of Electronic Publication: 2020 Mar 06.